ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS

Informations projet

UNITE4TB

N° de convention de subvention: 101007873

DOI

10.3030/101007873

Date de signature de la CE 29 Juin 2021

Date de début 1 Juin 2021

Date de fin 31 Mai 2028

Financé au titre de

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coût total

€ 185 000 000,00

Contribution de l’UE

€ 92 500 000,00

Coordonné par

STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUM
Netherlands

CORDIS fournit des liens vers les livrables publics et les publications des projets HORIZON.

Les liens vers les livrables et les publications des projets du 7e PC, ainsi que les liens vers certains types de résultats spécifiques tels que les jeux de données et les logiciels, sont récupérés dynamiquement sur OpenAIRE .

Livrables

Documents, reports (15)

Report of kick-off meeting

Report of kickoff meeting

Midterm recruitment report for phase 2B/C

Midterm recruitment report for phase 2B/CNote: this is a summary report for all phase 2B/C studies to be performed

Target product profile for stage-specific biomarkers - submitted to WHO and EMA

Target product profile for stage-specific biomarkers – submitted to WHO and EMA

Report of third annual consortium meeting
Communication and dissemination plan
Report of second annual consortium meeting
Annual report on status of posting results for phase 2B/C (1)
Establish CAG
Establish SAB and RAB
Annual report on status of posting results for phase 2A (1)
DAT training module developed
Attendance at key regional stakeholder events to discuss findings (1)
Report of first annual consortium meeting
Establish EAB
Code for pharmacodynamic models applicable phase 2A and 2B/C data (1)

Code for pharmacodynamic models applicable phase 2A and 2B/C data (1)

Websites, patent fillings, videos etc. (2)

Dissemination of educational materials through CME-webinars (1)
Visual identity and communication toolkit, including project website

Visual identity and communication toolkit including project website

Other (3)

Inaugural meeting with communication professionals of the partners in the consortium
Establish Young Investigators Group
Seminars for healthcare workers (1)

Publications

Peer reviewed articles (17)

Machine Learning and Pharmacometrics for Prediction of Pharmacokinetic Data: Differences, Similarities and Challenges Illustrated with Rifampicin

Auteurs: Keutzer L, You H, Farnoud A, Nyberg J, Wicha SG, Maher-Edwards G, Vlasakakis G, Moghaddam GK, Svensson EM, Menden MP, Simonsson USH, On Behalf Of The UNITE4TB Consortium
Publié dans: Pharmaceutics, 2022, ISSN 1999-4923
Éditeur: Multidisciplinary Digital Publishing Institute (MDPI)
DOI: 10.3390/pharmaceutics14081530

Candidate anti-tuberculosis medicines and regimens under clinical evaluation

Auteurs: Michael Hoelscher, David Barros-Aguirre, Masoud Dara, Norbert Heinrich, Eugene Sun, Christoph Lange, Simon Tiberi, Charles Wells
Publié dans: Clinical Microbiology and Infection, Numéro 30, 2024, Page(s) 1131-1138, ISSN 1198-743X
Éditeur: Blackwell Publishing Inc.
DOI: 10.1016/j.cmi.2024.06.016

A flexible multi‐metric Bayesian framework for decision‐making in Phase II multi‐arm multi‐stage studies

Auteurs: Suzanne M. Dufault; Angela M. Crook; Katie Rolfe; Patrick P. J. Phillips
Publié dans: Statistics in Medicine , 43 (3) pp. 501-513. (2024), Numéro 17, 2024, Page(s) 501-513, ISSN 0277-6715
Éditeur: John Wiley & Sons Inc.
DOI: 10.1002/sim.9961

Treatment-shortening regimens for tuberculosis: updates and future priorities

Auteurs: Francesca Saluzzo, Victor Abiola Adepoju, Raquel Duarte, Christoph Lange, Patrick P.J. Phillips
Publié dans: Breathe, Numéro 19 (3), October, 2023, ISSN 1810-6838
Éditeur: European Respiratory Society
DOI: 10.1183/20734735.0028-2023

Tuberculosis: current challenges and beyond

Auteurs: Raquel Villar-Hernández, Arash Ghodousi, Olha Konstantynovska, Raquel Duarte, Christoph Lange, Mario Raviglione on behalf of the UNITE4TB Consortium
Publié dans: Breath, 2023, ISSN 2073-4735
Éditeur: European Respiratory Society
DOI: 10.1183/20734735.0166-2022

Towards comprehensive clinical trials for new tuberculosis drug regimens: policy recommendations from a stakeholder analysis

Auteurs: Simone Villa, Pierpaolo de Colombani, Lucia Dall’Olio, Giuliano Gargioni, Mario Raviglione
Publié dans: BMJ Global Health, Numéro 2024;9: e014630, 2024, Page(s) 1-9, ISSN 2059-7908
Éditeur: BMJ Journals
DOI: 10.1136/bmjgh-2023-014630

Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies

Auteurs: Heyckendorf J, Georghiou SB, Frahm N, Heinrich N, Kontsevaya I, Reimann M, Holtzman D, Imperial M, Cirillo DM, Gillespie SH, Ruhwald M, Consortium UNITE4TB
Publié dans: Clinical Microbiology Reviews, Numéro 21 March 2022, 2022, Page(s) n/a, ISSN 1098-6618
Éditeur: American Society for Microbiology
DOI: 10.1128/cmr.00227-21

Developing biomarker assays to accelerate tuberculosis drug development: defining target product profiles 

Auteurs: Stephen H Gillespie , Andrew R DiNardo, Sophia B Georghiou, Wilber Sabiiti , Mikashmi Kohli, Ursula Panzner , Irina Kontsevaya6, Norbert Hittel, Lieven J Stuyver, Jia Bin Tan, Reinout van Crevel, Christoph Lange, Thuong Nguyen Thuy Thuong, Jan Heyckendorf, Morten Ruhwald, Norbert Heinrich
Publié dans: Lancet Microbe, 2024, Page(s) 1-11, ISSN 2666-5247
Éditeur: Elsevier ltd.
DOI: 10.1016/s2666-5247(24)00085-5

Advances in tuberculosis biomarkers: unravelling risk factors, active disease and treatment success

Auteurs: Jodie A. Schildkraut, Niklas Köhler, Christoph Lange, Raquel Duarte, Stephen H. Gillespie
Publié dans: Breathe, Numéro 20, 2024, Page(s) 240003, ISSN 1810-6838
Éditeur: European Respiratory Society
DOI: 10.1183/20734735.0003-2024

The importance of getting the dose right in the treatment of tuberculosis

Auteurs: Andrii Dudnyk, Wandini Lutchmun, Raquel Duarte, Christoph Lange, Elin M. Svensson
Publié dans: Breathe, Numéro 21, 2025, Page(s) 240177, ISSN 1810-6838
Éditeur: European Respiratory Society
DOI: 10.1183/20734735.0177-2024

Model‐Informed Once‐Daily Dosing Strategy for Bedaquiline and Delamanid in Children, Adolescents and Adults with Tuberculosis

Auteurs: Yu‐Jou Lin, Louvina E. van der Laan, Mats O. Karlsson, Anthony J. Garcia‐Prats, Anneke C. Hesseling, Elin M. Svensson
Publié dans: Clinical Pharmacology & Therapeutics, Numéro 117, 2025, Page(s) 1292-1302, ISSN 0009-9236
Éditeur: Nature Publishing Group
DOI: 10.1002/cpt.3536

Interoccasion variability in population pharmacokinetic models: identifiability, influence, interdependencies and derived study design recommendations

Auteurs: Emily Behrens, Sebastian G. Wicha
Publié dans: Journal of Pharmacokinetics and Pharmacodynamics, Numéro 52, 2025, ISSN 1567-567X
Éditeur: Kluwer Academic/Plenum Publishers
DOI: 10.1007/s10928-025-09966-7

The AMR Accelerator: from individual organizations to efficient antibiotic development partnerships

Auteurs: Josepine Fernow, Marie Olliver, William Couet, Sophie Lagrange, Meindert H. Lamers, Ole F. Olesen, Kristina Orrling, Michel Pieren, Derek J. Sloan, Juan José Vaquero, Timothy J. Miles, Anders Karlén
Publié dans: Nature Reviews Drug Discovery, Numéro 24, 2025, Page(s) 1-2, ISSN 1474-1776
Éditeur: Nature Publishing Group
DOI: 10.1038/d41573-024-00138-9

Implementing molecular tuberculosis diagnostic methods in limited-resource and high-burden countries

Auteurs: Anca Vasiliu, Antonia Morita Iswari Saktiawati, Raquel Duarte, Christoph Lange, Daniela Maria Cirillo on behalf of the UNITE4TB Consortium
Publié dans: Breath, 2023, ISSN 2073-4735
Éditeur: European Respiratory Society
DOI: 10.1183/20734735.0226-2022

Artificial intelligence in tuberculosis: a new ally in disease control

Auteurs: Mairi McClean, Traian Constantin Panciu, Christoph Lange, Raquel Duarte, Fabian Theis
Publié dans: Breathe, Numéro 20, 2024, Page(s) 240056, ISSN 1810-6838
Éditeur: European Respiratory Society
DOI: 10.1183/20734735.0056-2024

Rolling out new anti-tuberculosis drugs without diagnostic capacity

Auteurs: Tara Ness, Le Hong Van, Ilze Petermane, Raquel Duarte, Christoph Lange, Dick Menzies, Daniela Maria Cirillo
Publié dans: Breathe, Numéro 19(2), July, 2023, ISSN 1810-6838
Éditeur: European Respiratory Society
DOI: 10.1183/20734735.0084-2023

Standards for model-based early bactericidal activity analysis and sample size determination in tuberculosis drug development

Auteurs: Mockeliunas L, Faraj A, van Wijk RC, Upton CM, van den Hoogen G, Diacon AH, Simonsson USH
Publié dans: Front. Pharmacol., 2023, ISSN 1663-9812
Éditeur: Frontiers Media S.A.
DOI: 10.3389/fphar.2023.1150243

Non-peer reviewed articles (1)

UNITE4TB: a new consortium for clinical drug and regimen development for TB

Auteurs: Boeree, M. J.; Lange, C.; Thwaites, G; Paton, N ; de Vrueh, R.; Barros, D.; Hoelscher, M.; on behalf of the UNITE4TB Consortium
Publié dans: International Union Against Tuberculosis and Lung Disease, Numéro Volume 25, Number 11, 1 November 2021, 2021, Page(s) 886-889, ISSN 1027-3719
Éditeur: International Union Against Tuberculosis And Lung Disease/Union Internationale Contre la Tuberculose et les Maladies Respiratories
DOI: 10.5588/ijtld.21.0515